Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How Should Medicaid Pay For Cures? Sen. Grassley Likes Annuity Model

Executive Summary

Finance Committee chairman wants a provision allowing Medicaid to make installment payments for high-cost curative treatments in drug pricing legislation. But Democrats worry such a model might encourage high prices.

You may also be interested in...



Medicaid Rebate Ceiling Raised To 125% In Senate Legislation

Senate Finance Committee's drug pricing bill would also exclude authorized generics from calculation of average manufacturer prices and rebates and authorize installment-type payments for curative gene therapies.

As Washington Waits On Pricing Proposals, A Call For A Reset In R&D Debate

Policymakers should clarify link between high drug prices and innovation and figure out how to “rebalance” high prices with non-price innovation incentives before proceeding with policies aimed directly at lowering prices, Conti and David propose in the Health Affairs Blog.

Senate Bill Would Prevent Safety Label Carve-Outs From Delaying Approvals

Updated drug pricing bill would allow US FDA to approve generics even if innovator safety information is protected by exclusivity.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS125505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel